12.28
4.88%
-0.63
전일 마감가:
$12.91
열려 있는:
$12.87
하루 거래량:
60,337
Relative Volume:
1.10
시가총액:
$1.05B
수익:
$106.66M
순이익/손실:
$15.16M
주가수익비율:
-
EPS:
-
순현금흐름:
$6.37M
1주 성능:
-11.27%
1개월 성능:
-13.22%
6개월 성능:
-6.26%
1년 성능:
+0.00%
Gyre Therapeutics Inc Stock (GYRE) Company Profile
명칭
Gyre Therapeutics Inc
전화
(619) 949-3681
주소
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
GYRE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
GYRE | 12.17 | 1.05B | 106.66M | 15.16M | 6.37M | 0.00 |
VRTX | 451.27 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 754.08 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 588.30 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 250.47 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 106.54 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2021-04-29 | 재개 | Stephens | Overweight |
2021-02-10 | 개시 | Piper Sandler | Overweight |
2020-05-21 | 개시 | Raymond James | Outperform |
2019-01-04 | 개시 | Oppenheimer | Outperform |
2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
2017-06-12 | 개시 | Chardan Capital Markets | Buy |
2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
2016-06-30 | 개시 | Rodman & Renshaw | Buy |
모두보기
Gyre Therapeutics Inc 주식(GYRE)의 최신 뉴스
Short Interest in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Declines By 16.1% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 7.8%Here's Why - MarketBeat
Gyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023) - Yahoo Finance
Gyre Therapeutics Reports Q3 2024 Financial Results and Strategic Updates - TipRanks
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides - The Bakersfield Californian
Gyre Therapeutics Revenue Falls 20% as Phase 3 Trial Milestone Nears Critical Data | GYRE Stock News - StockTitan
VirTra Appoints Retired U.S. Army Lieutenant General Maria R. Gervais and Georgia POST Executive Director Mike Ayers to Board of Directors - The Manila Times
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis - The Manila Times
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.8%What's Next? - MarketBeat
AQR Capital Management LLC Invests $778,000 in Mativ Holdings, Inc. (NYSE:MATV) - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpStill a Buy? - MarketBeat
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt - Yahoo Finance
Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2% - Defense World
Coronation Fund Managers Ltd. Buys 1,044 Shares of The Sherwin-Williams Company (NYSE:SHW) - Defense World
Eaton Vance California Municipal Income Trust (NYSE:CEV) Major Shareholder Sells $282,451.70 in Stock - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Trading 3.3% HigherHere's What Happened - MarketBeat
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference - The Manila Times
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Down 7.0% in August - MarketBeat
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday - Benzinga
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 4.9% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 6.6% - MarketBeat
Gyre Therapeutics Inc (GYRE) Stock Price & Chart | Trade Now - Capital.com
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 8.9% - MarketBeat
Short Interest in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Grows By 5.4% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading 4.1% Higher - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 6.6% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading Volume - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Quotes, Forecast and News Summary - Benzinga
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Significant Growth in Short Interest - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 8.2% - MarketBeat
Vanguard Group Inc. Reduces Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up to $10.40 - MarketBeat
GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024 - InvestorPlace
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 3.9% - MarketBeat
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - BioSpace
Sidoti Events, LLC's Virtual August Micro-Cap Conference - AccessWire
Gyre Therapeutics (NASDAQ:GYRE) Trading 6.7% Higher - MarketBeat
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference - ForexTV.com
Gyre Therapeutics Welcomes Dr. Epstein to Leadership Team - TipRanks
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - StockTitan
Gyre Therapeutics (NASDAQ:GYRE) versus Insmed (NASDAQ:INSM) Critical Comparison - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 8.4% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 18.9% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 8.4% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 4.9% - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 67.9% in July - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 4.3% - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.3% - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Update - Defense World
Gyre Therapeutics Inc (GYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):